Interleukin-18 Promoter Polymorphism and Development of Antibodies to Surface Antigen of Hepatitis B Virus in Hemodialysis Patients
Open Access
- 10 August 2011
- journal article
- research article
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 35 (1), 1-8
- https://doi.org/10.1159/000329932
Abstract
Interleukin (IL)-18 is involved in hepatitis B virus (HBV) clearance and augments antibodies against surface antigen of HBV (anti-HBsAg) production during DNA vaccination. The IL-18 -1297C>T (rs360719) polymorphism may modulate the IL-18 expression. To determine the potential association of IL-18 -1297C>T polymorphism with development of anti-HBsAg in hemodialysis (HD) patients. The frequency of IL-18 -1297C>T alleles and genotypes was identified by polymerase chain reaction restriction fragment length polymorphism in 435 HD patients. Group 1 (n = 219) developed an anti-HBsAg titer >10 IU/l as a result of vaccination or HBV transmission. Group 2 (n = 216) included patients who did not develop an anti-HBsAg titer >10 IU/l in response to at least one full series of vaccination or HBV transmission. The significance of genotype frequency was tested using the Fisher exact test. In group 1, the frequencies of -1297CC, -1297CT and -1297TT genotypes were 7.3, 39.7 and 53.0%, respectively, and in group 2 they were 1.9, 42.1 and 56.0%, respectively. The odds ratio for CC versus CT + TT was 0.239 (95% CI 0.079-0.728, p = 0.010), and for CC versus TT it was 0.240 (95% CI 0.078-0.738, p = 0.009). In HD patients, the IL-18 -1297CC genotype may play a role in anti-HBsAg development in response to HBV surface antigen.Keywords
This publication has 29 references indexed in Scilit:
- Seroconversion rate to positivity for antibodies against core antigen of hepatitis B virus and duration of renal replacement therapyNephrology Dialysis Transplantation, 2010
- Antibodies to Core Antigen of Hepatitis B Virus in Patients on Renal Replacement Therapy: Association with Demographic, Clinical and Laboratory DataNephron Clinical Practice, 2009
- Co-delivery of plasmid-encoded cytokines modulates the immune response to a DNA vaccine delivered by in vivo electroporationVaccine, 2007
- Occult hepatitis B virus infection in dialysis patients: a multicentre surveyAlimentary Pharmacology & Therapeutics, 2005
- Occult hepatitis B virus infection in a North American adult hemodialysis patient populationHepatology, 2004
- Genetic adjuvants for DNA vaccinesVaccine, 2001
- Protective effect of hepatitis B vaccine in chronic hemodialysis patientsAmerican Journal of Kidney Diseases, 1999
- Responsiveness to Hepatitis B Vaccine in Immunocompromised Patients by Doubling the Dose SchedulingNephron, 1996
- HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysisKidney International, 1995
- Isolated Presence of Antibody to Hepatitis B Core Antigen in Dialysis Patients: Occurrence of Subclinical Hepatitis?American Journal of Kidney Diseases, 1989